Overview Financials News + Filings Key Docs Charts Ownership Insiders |
ENGLOBAL CORP (ENG)
|
Add to portfolio |
|
|
Price: |
$3.74
| | Metrics |
OS: |
40.9
|
M
| |
-886
|
% ROE
|
Market cap: |
$153
|
M
| |
-259
|
% ROIC
|
Net debt:
|
$864
|
k
| |
|
|
EV:
|
$154
|
M
| | | |
| | | | | |
TTM Valuation | | | |
EBITDA
|
($22.9)
|
M
| |
|
|
EBIT
|
($23.8)
|
M
| |
|
|
EPS |
($0.65)
| |
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
In millions, except per share items | Dec-31-22 | Dec-25-21 | Dec-26-20 | Dec-28-19 | Dec-29-18 | Dec-30-17 | Dec-31-16 | Dec-26-15 |
Revenues | 40.2 | 36.4 | 64.4 | 56.4 | 54.0 | 55.8 | 59.2 | 79.6 |
Revenue growth | 10.4% | -43.5% | 14.2% | 4.5% | -3.2% | -5.8% | -25.6% | -26.2% |
Cost of goods sold | 47.8 | 37.1 | 56.1 | 48.5 | 47.1 | 49.3 | 49.1 | 63.3 |
Gross profit | -7.7 | -0.7 | 8.3 | 7.9 | 6.9 | 6.4 | 10.1 | 16.3 |
Gross margin | -19.0% | -1.9% | 13.0% | 14.0% | 12.8% | 11.5% | 17.1% | 20.4% |
Selling, general and administrative | 14.1 | 12.8 | 8.8 | 9.3 | 10.0 | 12.6 | 13.4 | 14.2 |
EBITA | -18.3 | -13.5 | -0.4 | -1.4 | -3.1 | -6.1 | -3.1 | 2.3 |
EBITA margin | -45.6% | -37.0% | -0.6% | -2.5% | -5.7% | -11.0% | -5.3% | 2.9% |
Amortization of intangibles | | | | | | | 0.1 | 0.2 |
EBIT | -18.3 | -13.5 | -0.4 | -1.4 | -3.1 | -6.1 | -3.2 | 2.1 |
EBIT margin | -45.6% | -37.0% | -0.6% | -2.5% | -5.7% | -11.0% | -5.5% | 2.6% |
Pre-tax income | -18.5 | -5.6 | -0.5 | -1.4 | -5.6 | -6.2 | -3.4 | 2.3 |
Income taxes | 0.0 | 0.0 | 0.1 | 0.1 | 0.1 | 10.1 | -1.0 | -8.2 |
Tax rate | 0.0% | 0.0% | | | | | 30.5% | |
Net income | -18.5 | -5.7 | -0.6 | -1.5 | -5.7 | -16.3 | -2.3 | 10.5 |
Net margin | -46.1% | -15.6% | -1.0% | -2.6% | -10.5% | -29.2% | -4.0% | 13.2% |
|
Diluted EPS | ($0.52) | ($0.18) | ($0.02) | ($0.05) | ($0.21) | ($0.59) | ($0.08) | $0.38 |
Shares outstanding (diluted) | 35.6 | 31.9 | 27.5 | 27.4 | 27.5 | 27.4 | 27.7 | 28.0 |
|
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|